Cost-Effectiveness Analysis of Salmeterol/Fluticasone Propionate 50/500μg vs Fluticasone Propionate 500μg in Patients with Corticosteroid-Dependent Asthma V: Results

被引：0
|
作者：
Willem R. Pieters
Bo Lundbäck
Seema Sondhi
Martin J. Price
Robert M.A. Thwaites
机构：
[1] Elkerliek Ziekenhuis,Respiratory Unit
[2] National Institute for Working Life,Global Health Outcomes
[3] Glaxo Wellcome,undefined
来源：
PharmacoEconomics | 1999年 / 16卷
关键词：
Asthma; Adis International Limited; Fluticasone Propionate; Salmeterol; Formoterol;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Methods: An economic analysis was performed to compare the cost effectiveness of a new formulation combining salmeterol 50μg and fluticasone propionate 500μg in a multidose dry powder (Diskus™) inhaler (n = 167) with that of fluticasone propionate (FP) 500μg (n = 165) also delivered via the Diskus™ in patients with corticosteroid-dependent asthma. Clinical data were obtained from a recent European multicentre trial; the economic analysis adopted a Swedish healthcare perspective.
引用
收藏
页码：29 / 34
页数：5
相关论文
共 50 条
  • [31] FLUTICASONE PROPIONATE INTRANASAL STEROID - COST-EFFECTIVENESS VS ANTIHISTAMINES
    BERKA, C
    CHIN, W
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1994, 93 (01) : 165 - 165
  • [32] Cost-effectiveness of salmeterol/fluticasone propionate combination product 50/250 μg twice daily and budesonide 800 μg twice daily in the treatment of adults and adolescents with asthma
    Lundbäck, B
    Jenkins, C
    Price, MJ
    Thwaites, RMA
    RESPIRATORY MEDICINE, 2000, 94 (07) : 724 - 732
  • [33] Cost-Effectiveness and Cost-Utility of Beclomethasone/Formoterol versus Fluticasone Propionate/Salmeterol in Patients with Moderate to Severe Asthma
    Gerzeli, Simone
    Rognoni, Carla
    Quaglini, Silvana
    Cavallo, Maria Caterina
    Cremonesi, Giovanni
    Papi, Alberto
    CLINICAL DRUG INVESTIGATION, 2012, 32 (04) : 253 - 265
  • [34] Cost-Effectiveness and Cost-Utility of Beclomethasone/Formoterol versus Fluticasone Propionate/Salmeterol in Patients with Moderate to Severe Asthma
    Simone Gerzeli
    Carla Rognoni
    Silvana Quaglini
    Maria Caterina Cavallo
    Giovanni Cremonesi
    Alberto Papi
    Clinical Drug Investigation, 2012, 32 : 253 - 265
  • [35] COST-EFFECTIVENESS OF SALMETEROL/FLUTICASONE PROPIONATE COMBINATION VERSUS LEUKOTRIENE MONTELUKAST FOR THE CONTROL OF PERSISTENT ASTHMA IN CHILDREN
    Rely, K.
    Gonzalez, S. E.
    Alexandre, P. K.
    Salinas, G. E.
    VALUE IN HEALTH, 2010, 13 (07) : A323 - A324
  • [36] Cost effectiveness of fluticasone propionate and flunisolide in the treatment of corticosteroid-naive patients with moderate asthma
    Volmer, T
    Kielhorn, A
    Weber, HH
    Wiessmann, KJ
    PHARMACOECONOMICS, 1999, 16 (05) : 525 - 531
  • [37] Cost Effectiveness of Fluticasone Propionate and Flunisolide in the Treatment of Corticosteroid-Naive Patients with Moderate Asthma
    Timm Volmer
    Adrian Kielhorn
    Hans H. Weber
    Karl J. Wiessmann
    PharmacoEconomics, 1999, 16 : 525 - 531
  • [38] BUDGET IMPACT ANALYSIS OF INTRODUCTION FLUTICASONE PROPIONATE/SALMETEROL (500/50 MG) INTO THE BRAZILIAN NATIONAL DRUG FORMULARY
    Godoy, M. R.
    Bueno, R. L. P.
    VALUE IN HEALTH, 2009, 12 (07) : A525 - A525
  • [39] Fluticasone propionate/salmeterol 250/50 μg versus salmeterol 50 μg after chronic obstructive pulmonary disease exacerbation
    Ohar, Jill A.
    Crater, Glenn D.
    Emmett, Amanda
    Ferro, Thomas J.
    Morris, Andrea N.
    Raphiou, Ibrahim
    Sriram, Peruvemba S.
    Dransfield, Mark T.
    RESPIRATORY RESEARCH, 2014, 15
  • [40] Fluticasone propionate/salmeterol 250/50 μg versus salmeterol 50 μg after chronic obstructive pulmonary disease exacerbation
    Jill A Ohar
    Glenn D Crater
    Amanda Emmett
    Thomas J Ferro
    Andrea N Morris
    Ibrahim Raphiou
    Peruvemba S Sriram
    Mark T Dransfield
    Respiratory Research, 15
12345